The Tazuke Kofukai Foundation Medical Research Kitano Hospital
Osaka, Japan
NCT Number: NCT00919737
The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Phase 1 / Phase 2
Osaka, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Polifeprosan 20 with Carmustine 3.85%
Time frame: 12 months
Time frame: 12 months
Nobelpharma
Industry
A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02303678
Brain Diseases, Brain Neoplasms
Durham, North Carolina, United States
View Trial DetailsNCT03213678
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Birmingham, Alabama, United States
View Trial DetailsNCT04817254
Astrocytoma, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03746080
Astrocytoma, Glioblastoma
Palo Alto, California, United States
View Trial Details